Dilworth & Barrese, LLP announces association with IP2 Patentwalts GmbH
We are pleased to announce an exciting development in our firm’s thirty (30) year history which promises to expand its capacity for servicing its clients…
Examining Exergen For Patent Eligibility Clues
By Matthew Siegal Not every diagnosis patent is invalid under 35 U.S.C. § 101 for being directed to a law of nature. In Exergen Corp.…
Even the Value of The Smallest Salable Unit Must Be Apportioned
By Matthew Siegal Finjan, Inc. v. Blue Coat Sys., Inc In Finjan, Inc. v. Blue Coat Sys., Inc., 16-2520 (Fed. Cir. Jan. 10, 2018) (http://bit.ly/2nZxFg4),…
Dilworth & Barrese
Dilworth & Barrese, LLP is excited to announce that we have formed a strategic affiliation with fellow intellectual property firm, Dilworth IP, LLC. With this…
REHABILITATING OR STRENTHENING THE U.S. PATENT THAT MAY BE DEFECTIVE OR VUNERABLE TO THIRD PARTY VALIDITY CHALLENGE
REHABILITATING OR STRENTHENING THE U.S. PATENT THAT MAY BE DEFECTIVE OR VUNERABLE TO THIRD PARTY VALIDITY CHALLENGE By: Peter G. Dilworth The quality of a…
Read More